Eugene Consulting Inc.
408-25 Montgomery Ave
Toronto, ONM4R 0A1

August/September 2022 Report
CDC Recommends Novavax COVID-19 Vaccine for Adolescents - Aug 22, 2022
https://www.cdc.gov/media/releases/2022/s0822-novax-vaccine.html- CDC signed a decision memo stating that Novavax’s COVID-19 vaccine can be used asanother primary series option for adolescents ages 12 through 17- This recommendation follows FDA’s authorization to authorize the vaccine for this age
group under emergency use- This vaccine provides a more familiar type of COVID-19 vaccine technology - it packages
proteins of the COVID-19 virus alongside an adjuvant that helps the immune system
respond to the virus in the future
Novavax Vaccine offers better immunity against new variants - August 23, 2022
https://economictimes.indiatimes.com/news/india/novavaxs-protein-based-jab-offersbetter-immunity-against-new-variants-ceo-stanley-erck/articleshow/93718017.cms- The CEO of Novavax has stated that they have some evidence that their vaccine shows
effectiveness of up to a year
- They are working on getting data on this for the next three of four months- Novavax vaccine was the only one that went through ef icacy trials when the new
Omicron variants were circulating and data shows that it works with 90% plus
effectiveness against the variants- When looking at variants like BA4 and BA5, the vaccine seems to stimulate broadly
neutralizing antibodies
EIT Health- EIT Health was established in 2015, as a ‘knowledge and innovation community’ of theEuropean Institute of Innovation and Technology (EIT)- It is a network of best-in-class health innovators based by the EU- From 2016-2021, the have supported 1680+ start-ups and launched over 70 products
and services- The network consists of approximately 280 organizations from around the world- EIT Health is a non-pro it organization that is funded by the European Union, theirpartners and their contributors- List of partners: https://eithealth.eu/our-network/our-partners/- Examples of products and services developed by EIT: https://eithealth.eu/what-we-do/
product-and-service-development/

ff

f

f

What they do- Create an environment where innovators can explore new ideas and ind practicalresources to create products and services rooted in innovation- Help to initiate projects to ind solutions to problems

Eugene Consulting Inc.
408-25 Montgomery Ave
Toronto, ONM4R 0A1- This might be a new type of diagnostics, a device or therapy that can help to better
manage a disease or infrastructure to improve the organization of care
- The network works to bring the right people together to turn ideas into
commercially viable products and services
Focus Areas- EIT Health focuses on inding solutions to 6 urgent healthcare challenges
1) Reforming Care Pathways - focus on extending care pathways to provide end-to=end
care before the onset of disease through to end-of-life support. EIT is working on
optimizing long-term care to enable people with chronic conditions to live as well aspossible
2) Healthcare Transformation - EIT works on bringing together innovators and create asustainable healthcare system that can support an ageing society3) Harnessing Real-World Data - EIT’s goal is to exhaust the wealth of healthcare data
available across Europe to improve the lives of patients and citizens
4) Bringing Care Home - EIT tackles the health challenges of an ageing population byprioritizing innovative solutions that support healthcare delivery in the home and way
from the hospital, improving health outcomes5) Health in the Workplace - Seeing that work-related stress affects one in four employees
in Europe, EIT is working to improve workplace health at every level through better
education, improved personal awareness and helping to make healthy choices easier
6) Fostering Healthier Lives - Their goal is to encourage changes in lifestyle behaviours bycreating tools and incentives for patients that help protect their healthhttps://eithealth.eu/news-article/eit-to-support-eit-health-for-a-further-seven-years/ August 25, 2022
- Following a comprehensive assessment, EIT con irmed the partnership agreement
between EIT and EIT Health will continue for a further 7 years

fffff

https://eithealth.eu/news-article/incephalo-ag-receives-eit-health-gold-track-grant/ August 22, 2022
- InCephalo AG is a Switzerland-based preclinical biotechnology company founded in 2021
by leading experts in the ield of brain cancer- The company leverages its proprietary technology platform to develop compartmentlocked (C-Locked) therapies that are tailor-made for local application for brain cancer- InCephalo’s platform aims to deliver therapies to offer better response rates, more
prolonged survival and improved quality of life to patients with brain cancer- InCephalo AG has received the competitive EIT Health Gold Track grant to expand its
compartment-locked technology to novel targets to ight brain cancers- The grant is inanced by the Swiss State Secretariat for Education, Research andInnovation (SERI)

Eugene Consulting Inc.
408-25 Montgomery Ave
Toronto, ON
M4R 0A1

https://eithealth.eu/news-article/estonian-healthtech-start-up-antegenes-raises-e2-3m/ August 8, 2022
- EIT Health-supported start-up, Antegenes, has raised 2.3 million euros in funding to bringits innovative genetic tests for personalized cancer prevention into broader use inhealthcare, scale the team and expand to new foreign markets- Funding was received from investors, Enterprise Estonia and EIT Health- Antegenes’ novel genetic tests assess a patient’s cancer risks and include clinicalrecommendations for further personalized cancer prevention- Trials are based on innovative polygenic risk score technology, which helps to clarify anindividual’s genetic predispositions to cancer- This allows for more accurate prevention and early detection measures, which is crucial
in ighting cancer- The tests are currently used to determine the genetic risk of four cancers, in breast
cancer, prostate cancer, colon cancer, and skin melanoma- Antegenes raised 1.6 million euros from investors in a seed round led by Pipedrive cofounder Timo Rein, Pipedrive’s irst investor Peep Vain and entrepreneurs Care Kuristand Andreas Henn Otsmaa- The investments make it possible to bring personalized cancer prevention into wider use
in healthcare including in new markets- In addition, Antegenes has received 2 grants to bring research-intensive innovation tointernational healthcare- BRIGHT project, inanced with 2.28 million euros by EIT Health, of which 500,000
euros is a grant to Antegenes- The project centers around Antegenes and the breast cancer genetic risk test
AnteBC- The project aims to implement the AnteBC test in breast cancer precision
prevention in Estonia, Portugal and Sweden, with further developments inEurope more broadly- The second grant is through the Norway Grants Green ICT programme, which
supports business cooperation between Estonia and Norway- The goal of the 200,000 euro funding is to implement the breast cancer
genetic risk test AnteBC as part of a breast cancer screening routine inNorway

fff

InCephalo Therapeutics - https://incephalo.com/- InCephalo has positioned themself as a CLocked Fc-Fusion Cytokine and antibody
company- The company develops exclusively local treatments for neurological diseases, with a focus
on cancers in the brain- The proprietary Compartment Lock technology, also called C-Lock, retains biologics, thatare applied locally behind the blood brain barrier, in the central nervous system (CNS)
and once they leave the CNS, degrades them rapidly in the systemic compartment

Eugene Consulting Inc.
408-25 Montgomery Ave
Toronto, ON
M4R 0A1- This signi icantly improves local CNS therapy- One of the biggest challenges for CNS (brain) therapies is getting the drug into the Brianand for the drug to remain at high concentration at the disease site
- There are currently 2 approaches by which biologics such as antibodies or FcFusion molecules are being administered to the brain - either through (i) systemic
application or (ii) local injection- The former’s (i) most signi icant disadvantage is that over 99% of the drug does notenter the brain compartment and therefore possess a high risk of adverse effects inother places of the body
- While (ii) locally applied drugs have a higher local concentration, they start to leakout of the brain compartment and, in particular biologics, can accumulate in thebody- InCephalo’s approachfff- InCephalo’s Compartment Lock technology, also called C-Lock allows tailor-mademolecules for local administration.
- These have two properties:- (i) they stay in the desired compartment for an extended period of time
- (ii) if they leak, they are rapidly degraded.
- The combination of both properties will signi icantly reduce the drug’s overall exposure
to the body and allow for a higher local dosing window with considerably reduced
chances for adverse events in other parts of the body
- The technology can be applied to antibodies, Fc-fusion proteins and similar biologicaldrug formats

Eugene Consulting Inc.
408-25 Montgomery Ave
Toronto, ONM4R 0A1- C-Locked pipeline: InCephalo has an IP portfolio revolving around its Compartment Locktechnology- This toolbox allows to create tailor-made molecules for local application of drugs
behind the blood brain barrier- The drug discovery team is currently applying the C-Lock technology on a variety of
established and promising new targets for novel therapies of cancers in the Brian- First drug candidate - InC01: InCephalo’s Compartment Locked IL-12 cytokine (InC01) isa locally applied biological drug candidate designed for the treatment of cancers in thebrain- It was awarded Orphan Drug Designation by EMA- IL-12 is a potent proin lammatory cytokine and a master regulator of a robust antitumor immune response.
- It can transform the “cold” immunsuppressive brain tumor microenvironment into
an in lammatory “hotspot”.
- It has shown treatment ef icacy in countless preclinical models alone or in various
combination regimens and encouraging signs of ef icacy in irst-in-human trials.
- In C01, InCephalo’s C-Locked IL-12 cytokine is better retained at the tumor and if itleaks into the bloodstream, is rapidly degraded.
- This expanded dosing window now allows physicians to use the optimal dose
without the constraints of systemic toxicity.

ff

f

f

f

Antegens - https://antegenes.com/- Antegenes is an innovative-oriented Estonian medical technology company founded in2018- They are a registered healthcare service provider of medical genetics, oncology andlaboratory services in Estonia

Eugene Consulting Inc.
408-25 Montgomery Ave
Toronto, ON
M4R 0A1- Antegenes uses high-tech polygenic risk score technology to assess one’s genetic risk ofdeveloping common ccancers- The polygenic risk score sums up information over hundreds to thousands ofgenetic variants in the human genome- By combing the polygenic risk score with a person’s backgoround, the task
calculates a person’s risk of developing cancer and provides medical advice on
prevention and early detection- All of their tests are registered with the Estonian Health Board on the basis of the in vitro
Diagnostic Medical Devices Directive- They also have a DNA upload service for cancer risk tests which accepts DNA data from
23andme, MyHeritage, Genes for Good, Ancestry DNA, Family Tree DNA or Estonian
Genome Center
Types of test available
1) Genetic risk test of common cancers in women (includes risk assessment of breast
cancer, colorectal cancer, and melanoma with medical recommendations)
2) Genetic risk test of common cancers in men (includes risk assessment of prostatecancer, colorectal cancer, melanoma with medical recommendations
3) Genetic risk test for breast cancer (includes risk assessment of 2803 genetic breast
cancer variants with medical recommendations)4) Genetic risk test for prostate cancer (includes risk assessment of 121 genetic
prostate cancer variants with medical recommendations)
5) Genetic risk test for colorectal cancer (includes risk assessment of 91 genetic
colorectal cancer variants with medical recommendations)
6) Genetic risk test for melanoma (includes genetic consultation, risk assessment of
28 genetic melanoma variants with medical recommendations )Services they offer
1) Post-genetic counselling- After receiving the results, users have the opportunity to register for a post-test genetic
counselling with Antegnes doctors- During the consultation, the results of the analysis are explained on the basis of the test
report and all questions are answered- The consultation is conducted through Zoom - however, it is also possible to come to ourclinic or get a telephone consultation2) Pre-test genetic counselling- Before ordering genet tests, users can register for a pre-test genetic counselling- During the pre-test consultation, users can ask for more information about the tests- Suitable tests are suggested and based on family history, the need to test for individual
genes in hereditary tumours are also discussed

Eugene Consulting Inc.
408-25 Montgomery AveToronto, ONM4R 0A13) Oncology consultation- A consultation with an oncologist includes professional medical advice in the ield ofmalignant tumors- The consultation can include advice in the ields of prevention, genetic predisposition,
diagnosis and treatment

ff

Public Health Programs they Offer- Breast cancer precision prevention program- Prostate cancer precision prevention program- Colorectal cancer precision prevention program- Skin melanoma precision prevention program